Literature DB >> 11781691

The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation.

A Bergman1, Z Einbeigi, U Olofsson, Z Taib, A Wallgren, P Karlsson, J Wahlström, T Martinsson, M Nordling.   

Abstract

The most recurrent BRCA1/BRCA2 mutation in Sweden is the BRCA1 mutation 3171ins5. In the western part of Sweden this mutation accounts for as much as 77% of identified mutations in these two genes. Our aim was to analyse in detail the haplotype and founder effects of the 3171ins5 and furthermore attempt to estimate the time of origin of the mutation. In the study we included eighteen apparently unrelated families with hereditary breast and/or ovarian cancer. At least one individual in each family had previously tested positive for the 3171ins5 mutation. Polymorphic microsatellite markers were used for the haplotype analyses. The markers were located within or flanking the BRCA1 gene spanning a region of 17.3 cM. We found several different haplotypes both for disease alleles and for the normal alleles. However, a conserved haplotype of 3.7 cM was observed in the 3171ins5 carriers spanning over four markers located within or very close to the BRCA1 gene. As this haplotype was not present in any of the normal controls it is highly likely that this is a mutation identical by descent, i.e. a true founder. The results from the haplotype analyses were used to estimate the age of the mutation. Estimations based on the P(excess) and linkage disequilibrium gives a first appearance of the mutation sometime around the 6th century, approximately 50 generations ago.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11781691     DOI: 10.1038/sj.ejhg.5200704

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  14 in total

1.  Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden.

Authors:  Zakaria Einbeigi; Annika Bergman; Jeanne M Meis-Kindblom; Anna Flodin; Cecilia Bjursell; Tommy Martinsson; Lars-Gunnar Kindblom; Jan Wahlström; Arne Wallgren; Margareta Nordling; Per Karlsson
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

Review 2.  Mutations in context: implications of BRCA testing in diverse populations.

Authors:  Gabriela E S Felix; Yonglan Zheng; Olufunmilayo I Olopade
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

3.  A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.

Authors:  Annika Bergman; Anna Flodin; Yvonne Engwall; Eva L Arkblad; Kerstin Berg; Zakaria Einbeigi; Tommy Martinsson; Jan Wahlström; Per Karlsson; Margareta Nordling
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

4.  A novel 3-bp deletion in the PANK2 gene of Dutch patients with pantothenate kinase-associated neurodegeneration: evidence for a founder effect.

Authors:  P Rump; H H Lemmink; C C Verschuuren-Bemelmans; P M Grootscholten; J M Fock; S J Hayflick; S K Westaway; Y J Vos; A J van Essen
Journal:  Neurogenetics       Date:  2005-10-21       Impact factor: 2.660

5.  Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry.

Authors:  Bifeng Zhang; James D Fackenthal; Qun Niu; Dezheng Huo; Walmy E Sveen; Tiffani DeMarco; Clement A Adebamowo; Temidayo Ogundiran; Olufunmilayo I Olopade
Journal:  Fam Cancer       Date:  2008-08-05       Impact factor: 2.375

6.  Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.

Authors:  Rodrigo Santa Cruz Guindalini; Andrew Song; James D Fackenthal; Olufunmilayo I Olopade; Dezheng Huo
Journal:  Cancer       Date:  2016-03-15       Impact factor: 6.860

7.  NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer.

Authors:  Janice L Berliner; Angela Musial Fay; Shelly A Cummings; Brittany Burnett; Todd Tillmanns
Journal:  J Genet Couns       Date:  2012-11-28       Impact factor: 2.537

8.  BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.

Authors:  Henriette Roed Nielsen; Mef Nilbert; Janne Petersen; Steen Ladelund; Mads Thomassen; Inge Søkilde Pedersen; Thomas V O Hansen; Anne-Bine Skytte; Åke Borg; Christina Therkildsen
Journal:  Fam Cancer       Date:  2016-10       Impact factor: 2.375

9.  Multiple local and recent founder effects of TGM1 in Spanish families.

Authors:  Laura Fachal; Laura Rodríguez-Pazos; Manuel Ginarte; Jaime Toribio; Antonio Salas; Ana Vega
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

10.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.